Ultragenyx Pharmaceutical Inc.RARENASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank89
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-71.32%
↑ 100% vs avg
Percentile
P89
Within normal range
Streak
3 yr
Consecutive growthExpanding
Average
-19720.07%
Historical baseline
PeriodValueYoY Change
TTM-71.32%+14.8%
2024-83.72%+29.6%
2023-118.93%+32.5%
2022-176.28%-51.0%
2021-116.77%-126.4%
2020-51.58%+86.3%
2019-375.81%-9.0%
2018-344.81%+97.1%
2017-11964.51%+93.5%
2016-183896.99%-